
The third wave of corona infection will not have much effect on children. The World Health Organization (WHO) and the All India Institute of Medical Sciences (AIIMS) have claimed this in their seroprevalence survey. Because of the dangerous variant of Corona, fears of a third wave are being expressed in India, but now the claim of WHO and AIIMS in a new study is going to give relief.
According to the survey, the SARS-CoV-2 seropositivity rate is higher in children than in adults. Seropositivity refers to the physical ability to mount a natural immune response to the virus. Puneet Mishra, Professor of Community Medicine at Delhi AIIMS, said that seroprevalence was found to be very high at 74.7% in the refugee colonies of South Delhi.
This figure is the highest in any serosurvey conducted so far. According to the survey, even before the second wave, seroprevalence among children below 18 years living in south Delhi was 73.9%. More seroprevalence will act as a shield for children against the third wave.
10 thousand samples were taken from five states
For this survey, 10 thousand samples were taken from 5 states. At present, in the report that has come, 4500 samples from 4 states have been made the basis. In the next two three months, the complete report of 10 thousand sample sizes of the five states will come.
The mean ages for the study sites in Delhi Urban, Delhi Rural, Bhubaneswar, Gorakhpur, and Agartala were 11 years, 12 years, 11 years, 13 years, and 14 years. The data for the study was collected between 15 March 2021 and 10 June 2021. The ELISA kit was used to assess total serum antibodies against SARS-CoV-2, according to the researchers. This kit will detect the presence of antibodies to the coronavirus in the human body.
Sputnik V to bring booster shot against Delta variant
Here, the Russian vaccine Sputnik V has said that it will soon provide a booster shot. This booster dose will prove to be effective on the first Delta variant of the Coronavirus found in India. Along with this, the company has said that it will soon work with other vaccine manufacturers in the war against Corona.
Let us tell you that Sputnik V is the world's first corona vaccine, which was made by Russia's Gamalya Research Center last year. Sputnik V is the third vaccine to be used in India after Coveshield and Covaxin. It is being prepared by Hyderabad-based pharma company Dr. Reddy in collaboration with a Russian company.
Phase III data not given to WHO: Bharat Biotech
The country's leading vaccine maker Bharat Biotech has denied reports of Covaxin's Phase III data being submitted to the World Health Organization (WHO). The company said on Thursday that such reports are wrong that the company has given data of the third phase of the Covaxin vaccine to the WHO.
The Prime Minister has said that the election should take serious note of Mamata Banerjee's reply
Allu Arjun and Rashmika Mandanna starrer 'Pushpa 2: The Rule' had a record-breaking opening at th
DGCA Action: DGCA's big action on SpiceJet, 50 percent flights banned for 8 weeks
Action Against SpiceJet: The Directorate General of Civil Aviation (DGCA), taking major action on
Why was voting held in Kerala to elect a Russian President, people voted enthusiastically
Kerala vote for Russian President Voting for the presidential election is going on in Russia. Vot
Shiv Sena (UBT) leader Sanjay Raut on Sunday criticized Maharashtra Navnirman Sena (MNS) chief Ra
Fraud: In which case fugitive diamond trader Mehul Choksi is wanted in India, know what is PNB scam
India's fugitive diamond trader Mehul Choksi wanted in a scam of thousands of crores, is once aga
'Pushpa 2' is one of the most awaited films of this year. The audience is eagerly waiting for eve
Eye Flu: The continuous rains during the monsoon season have become a cause of trouble for people
UP Chief Minister Yogi Adityanath, while addressing the Legislative Council in the budget session
Pakistan ranks first in the list of 82 countries most affected by China: Report
Radio Free Europe/Radio Liberty reported that a new study measuring Beijing's growing global domi